Impact of a new reimbursement program on hepatitis B antiviral medication cost and utilization in Beijing, China

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Qiu, Qian ^a   Li, Yan ^b   Duan, Xiao Wan ^b   Yang, Li Kun ^b   Chen, Yu ^b   Li, Hui ^a   Wang, Li ^a   Duan, Zhong Ping ^b  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; ENTECAVIR; LAMIVUDINE; TELBIVUDINE;

ADULT; AGE; ARTICLE; CHINA; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG UTILIZATION; FEMALE; GENDER; HEALTH CARE POLICY; HEALTH INSURANCE; HEPATITIS B; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; REIMBURSEMENT; RETROSPECTIVE STUDY; SCORING SYSTEM; ECONOMICS; HEALTH SERVICE; HEPATITIS B, CHRONIC; HOSPITAL; STATISTICS AND NUMERICAL DATA;

ANTIVIRAL AGENTS; CHINA; DRUG COSTS; DRUG UTILIZATION; FEMALE; HEALTH SERVICES; HEPATITIS B, CHRONIC; HOSPITALS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; RETROSPECTIVE STUDIES;

EID: 84908042287     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109652     Document Type: Article

References (23)

1. Liang X, Bi S, Yang W, Wang L, Cui G, et al. (2009) Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis B vaccination. Vaccine 27: 6550-6557.
2. Lu FM, Zhuang H (2009) Management of hepatitis B in China. Chin Med J (Engl) 122: 3-4.
3. Lu J, Xu A, Wang J, Zhang L, Song L, et al. (2013) Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. BMC Health Serv Res 13: 37.
4. Yang BM, Kim DJ, Byun KS, Kim HS, Park JW, et al. (2010) The societal burden of HBV-related disease: South Korea. Dig Dis Sci 55: 784-793.
5. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, et al. (2006) A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4: 936-962.
6. EASL (2009) EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 50: 227-242.
7. Chinese Society of Hepatology and Chinese Society of Infectious Diseases CMA (2011) The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi 19: 13-24.
8. Liaw YF (2009) Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 51: 403-410.
9. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, et al. (2008) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2: 263-283.
10. Available: http://www.bjstats.gov.cn/Accessed 2014 Sep 17.
11. Liaw YF, Kao JH (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int: 531-561.
12. Min H, Wen C (2009) Assessment of Total Economic Burden of Chronic Hepatits B (CHB)-Related Disease in Beijing and Guangzhou, China. Value in health 12: S89-S92.
13. Chang TT, Suh DJ (2008) Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. Hepatol Int 2: 19-27.
14. Kobashi H, Miyake Y, Ikeda F, Yasunaka T, Nishino K, et al. (2011) Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res 41: 405-416.
15. Janssen HL, Reijnders JG (2009) Treatment with nucleos(t)ide analogues in chronic hepatitis B: where does the road map lead us? J Hepatol 51: 1-3.
16. Osborn M (2011) Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist 4: 55-64.
17. Buti M, Morillas RM, Prieto M, Diago M, Perez J, et al. (2012) Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients. Eur J Gastroenterol Hepatol 24: 535-542.
18. Yuen MF, Lai CL (2011) Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol 26 Suppl 1: 138-143.
19. Fattovich G (2003) Natural history and prognosis of hepatitis B. Semin Liver Dis 23: 47-58.
20. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, et al. (2002) Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 36: 263-270.
21. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, et al. (2000) Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 46: 420-426.
22. Yoon EL, Yim HJ, Lee HJ, Lee YS, Kim JH, et al. (2011) Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: two-year follow-up data. J Clin Gastroenterol 45: 893-899.
23. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, et al. (2011) Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 53: 62-72.